NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, pharmaceuticals
TL;DR
NRX Pharma filed an 8-K on 4/17/25. Standard update.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, reporting other events and financial statements. The company, formerly known as Big Rock Partners Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations industry.
Why It Matters
This filing indicates NRX Pharmaceuticals is providing updates on its corporate activities and financial status to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate updates and financial information, not indicating any specific new risks.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- Delaware (location) — State of incorporation
- April 17, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for NRX Pharmaceuticals, Inc.?
The filing is a Current Report on Form 8-K, used to announce material events that shareholders should know about, specifically noting 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K report filed with the SEC?
The report was filed on April 17, 2025.
What was NRX Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Big Rock Partners Acquisition Corp.
In which state is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for NRX Pharmaceuticals, Inc.?
The SIC code for NRX Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).